

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 29
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	

b)	LEI	5493000H2TVU1E01D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 5
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 11
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3921	19
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the	Acquisition of Ordinary Shares following the re-investment of

d)	Nature of the transaction	Repurchase of Ordinary Shares following share investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3921	3
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3921	76
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3921	29
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.3921	48
d)	Aggregated information	N/A (single transaction)	

	Aggregated volume Price	
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 62
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 58
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s) £16.4016	Volume(s) 1
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
----	--	--	--

a)	Name	Victoria Whyte	
b)	Position/status	SVP & Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ("Ordinary Shares") ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	123
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Iain Whyte	
b)	Position/status	PCA of Ms V Whyte (SVP & Company Secretary)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	1,152

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Emma Walmsley					
b)	Position/status	Chief Executive Officer					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£16.4016</td><td>105.836</td></tr></table>	Price(s)	Volume(s)	£16.4016	105.836	
Price(s)	Volume(s)						
£16.4016	105.836						
d)	Aggregated information Aggregated volume Price	N/A (single transaction)					
e)	Date of the transaction	2025-10-09					
f)	Place of the transaction	London Stock Exchange (XLON)					

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	1,233.149
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	1,024.598
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the	2025-10-09	

	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Sally Jackson				
b)	Position/status	SVP, Global Communications and CEO Office				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£16.4016</td><td>453.008</td></tr></table>	Price(s)	Volume(s)	£16.4016	453.008
Price(s)	Volume(s)					
£16.4016	453.008					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-10-09				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dylan Jackson
b)	Position/status	PCA of Sally Jackson (SVP, Global Communications and CEO Office)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

	transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	140.210
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	6,278.135
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Regis Simard				
b)	Position/status	President, Global Supply Chain				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£16.4016</td><td>2,616.351</td></tr></table>	Price(s)	Volume(s)	£16.4016	2,616.351
Price(s)	Volume(s)					
£16.4016	2,616.351					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-10-09				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s) £16.4016	Volume(s) 2,144.723
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Kate Thomson	
b)	Position/status	PCA of Philip Thomson (President, Global Affairs)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s) £16.4016	Volume(s) 109.382
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Deborah Waterhouse

a)	Name	Global Warehouse				
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ("Ordinary Shares") ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£16.4016</td><td>1,279.528</td></tr></table>	Price(s)	Volume(s)	£16.4016	1,279.528
Price(s)	Volume(s)					
£16.4016	1,279.528					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-10-09				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Tony Wood	
b)	Position/status	Chief Scientific Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	1 270 306

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Victoria Whyte					
b)	Position/status	SVP & Company Secretary					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£16.4016</td><td>1.332</td></tr></table>	Price(s)	Volume(s)	£16.4016	1.332	
Price(s)	Volume(s)						
£16.4016	1.332						
d)	Aggregated information Aggregated volume Price	N/A (single transaction)					
e)	Date of the transaction	2025-10-09					
f)	Place of the transaction	London Stock Exchange (XLON)					

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Elizabeth McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		43.7375	26
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-10	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Charles Bancroft	
b)	Position/status	Senior Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		43.7375	340
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-10	

f)	Place of the transaction	New York Stock Exchange (XNYS)
----	--------------------------	--------------------------------

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s) 43.7375	Volume(s) 28
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-10	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044

	financial instrument	ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		43.7375	34
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-10	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Harry Dietz	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		43.7375	32
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-10	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
----	--	--	--

a)	Name	Dr Jeannie Lee	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s) 43.7375	Volume(s) 13
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-10-10	
f)	Place of the transaction	New York Stock Exchange (XNYS)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Vishal Sikka	
b)	Position/status	Independent Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025	
c)	Price(s) and volume(s)	Price(s) 43.7375	Volume(s) 99

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-10-10
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFFWFLDEISEFS